{
  "docId": "019de073-d546-7099-b69b-fc409bd054ba",
  "docSlug": "a8472da99eed55bdf1e59eb3c42372d9",
  "documentTitle": "Silo Pharma | Investor Presentation Deck | 24 slides",
  "authorId": "silo-pharma",
  "authorName": "Silo Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 24,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "context",
  "function": "establish_context",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "Slide 12 of a pitch deck.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-d546-7099-b69b-fc409bd054ba/12",
  "deckHref": "/decks/019de073-d546-7099-b69b-fc409bd054ba",
  "deckJsonHref": "/decks/019de073-d546-7099-b69b-fc409bd054ba.json",
  "deckAnchorHref": "/decks/019de073-d546-7099-b69b-fc409bd054ba#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.65,
        "y": 0.23
      },
      "kind": "list",
      "text": "Regulatory Pathway and Results\n- 505(b)(2) Pathway\n- Preclinical testing and proof-of-concept led by inventor Dr. Christine Denny of Columbia University\n- Drug showed reduced anxiety in animal studies\n- May reduce behavioral despair\n- Scientific research agreement with Dr. Denny's lab",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "091c7ae6-e856-4e66-8595-9ddca74f26c4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.34,
        "y": 0.6
      },
      "kind": "list",
      "text": "Technology\n- Developed by Columbia University\n- Novel drug combines two approved therapeutics\n- Targets NDMARS and 5HT4Rs to treat cognitive and neuropsychiatric symptoms in Alzheimer's",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "304bdbc6-3ea4-4103-972d-75e084b11909",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.34,
        "y": 0.23
      },
      "kind": "list",
      "text": "Market Opportunity: Alzheimer's Disease\n- 6.5 million Americans suffer from Alzheimer's and related diseases\n- ~1 in 9 Americans 65+ have Alzheimer's\n- U.S. market for relevant drugs expected to reach $5 billion by 2027",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ba0fe04-e4eb-45f4-ace3-aee413668806",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.22,
        "x": 0.055,
        "y": 0.33
      },
      "kind": "title",
      "text": "SPC-14 Targeting Alzheimer's",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64df9c06-be45-44f1-b8bf-de7e087a44f2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.33,
        "x": 0.107,
        "y": 0.075
      },
      "kind": "title",
      "text": "Columbia University CELA",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d012d29-ddd4-458e-9ccc-02f4616d9e12",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 9,
      "beatId": "7eef8438-24a9-41be-8257-c3233f0d4ebf",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The solution is presented in the Zylö Therapeutics Joint Venture and UMB License Agreement sections",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 13,
      "from": 12,
      "name": "Voice Of Customer",
      "slug": "51-voice-of-customer",
      "bestFor": "Product strategy, customer experience, market research",
      "matchId": "94f0c355-ccb6-4143-8394-ffb96a1ebac7",
      "evidence": "The deck presents SPC-14 and SPC-15 as solutions for these conditions",
      "position": 0,
      "objective": "To understand the needs of patients with Alzheimer's and stress-induced affective disorders",
      "structure": "What Customers Say (Verbatim) -> The Pattern Across Voices -> The Insight -> The Response",
      "confidence": 0.6,
      "description": "Let customer quotes and feedback drive the narrative and validate the insight"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}